[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Amylyx Pharmaceuticals Inc (AMLX)

Amylyx Pharmaceuticals Inc (AMLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,689,589
  • Shares Outstanding, K 111,186
  • Annual Sales, $ 0 K
  • Annual Income, $ -144,740 K
  • EBIT $ -159 M
  • EBITDA $ -164 M
  • 60-Month Beta -0.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.90

Options Overview Details

View History
  • Implied Volatility 203.30% (+1.98%)
  • Historical Volatility 58.99%
  • IV Percentile 97%
  • IV Rank 69.09%
  • IV High 275.22% on 08/03/26
  • IV Low 42.53% on 04/30/26
  • Expected Move (DTE 14) 1.87 (7.73%)
  • Put/Call Vol Ratio 5.00
  • Today's Volume 6
  • Volume Avg (30-Day) 2,348
  • Put/Call OI Ratio 0.62
  • Today's Open Interest 49,538
  • Open Int (30-Day) 21,304
  • Expected Range 22.32 to 26.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.36
  • Number of Estimates 3
  • High Estimate $-0.33
  • Low Estimate $-0.39
  • Prior Year $-0.37
  • Growth Rate Est. (year over year) +2.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.52 +45.46%
on 07/17/26
24.58 -2.26%
on 08/07/26
+5.86 (+32.25%)
since 07/07/26
3-Month
12.44 +93.17%
on 05/19/26
24.58 -2.26%
on 08/07/26
+8.83 (+58.09%)
since 05/07/26
52-Week
7.48 +221.26%
on 08/08/25
24.58 -2.26%
on 08/07/26
+16.19 (+206.51%)
since 08/07/25

Most Recent Stories

More News
Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results

Last participant completed final study visit in the 16-week double-blind period of the pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia; topline data on track and anticipated...

AMLX : 24.22 (+0.12%)
Can Amylyx Still Call This a Pipeline Story After Thursday?

Barchart Research What to Expect from AMLX Earnings AMLX Generated August 5, 2026 Current Price $21.85 EPS Estimate $$-0.36 Consensus Rating Strong Buy Average Move 4.87% Can Amylyx Still Call This a Pipeline...

AMLX : 24.22 (+0.12%)
Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its second quarter 2026 financial results on Thursday, August 6, 2026. Amylyx’s senior management team...

AMLX : 24.22 (+0.12%)
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...

AMLX : 24.22 (+0.12%)
Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the presentation of data from its first-in-human, dose-ranging Phase 1 LUMINA trial of AMX0114 at...

AMLX : 24.22 (+0.12%)
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced two poster presentations at the upcoming Endocrine Society’s Annual Meeting (ENDO 2026), taking...

AMLX : 24.22 (+0.12%)
Amylyx Stock: Why the Full Pipeline Story Matters

Amylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX shares

AMLX : 24.22 (+0.12%)
MRK : 127.74 (-0.49%)
REGN : 774.98 (+0.37%)
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation

Peer-reviewed publication reports Week 24 and Week 48 results from Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome, reinforcing consistency of observed stabilization or improvement across multiple...

AMLX : 24.22 (+0.12%)
Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus

Amylyx Pharmaceuticals (NASDAQ:AMLX) is preparing for a pivotal Phase 3 readout for AVEXITIDE, its lead asset for post-bariatric hypoglycemia, or PBH, with data from the LUCIDITY trial expected in the...

AMLX : 24.22 (+0.12%)
Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

Topline data readout from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia on track; anticipated in Q3 2026 ...

AMLX : 24.22 (+0.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Amylyx Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It focuses on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 28.59
2nd Resistance Point 26.48
1st Resistance Point 25.33
Last Price 24.22
1st Support Level 22.07
2nd Support Level 19.96
3rd Support Level 18.81

See More

52-Week High 24.58
Last Price 24.22
Fibonacci 61.8% 18.05
Fibonacci 50% 16.03
Fibonacci 38.2% 14.01
52-Week Low 7.48

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.